Viking Therapeutics, Inc. (VKTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.5800 |
| Open | 3.5800 |
| Bid | 3.6800 x 2200 |
| Ask | 3.7500 x 1000 |
| Day's Range | 3.5800 - 3.7700 |
| 52 Week Range | 2.0200 - 7.2000 |
| Volume | |
| Avg. Volume | 1,144,232 |
| Market Cap | 294.163M |
| Beta (5Y Monthly) | 1.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Viking Therapeutics to Participate in Fireside Chat at BTIG Biotechnology Conference 2022
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will participate in a fireside chat as part of the BTIG Biotechnology Conference 2022. The conference will take place August 8-9, 2022.
- PR Newswire
Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2022, and provided an update on its clinical pipeline and other corporate developments.
- PR Newswire
Viking Therapeutics to Report Financial Results for Second Quarter 2022 on July 27, 2022
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the second quarter 2022, after the market close on Wednesday, July 27, 2022.
